More than a mood disorder: Study reveals depression ages brain faster than normal
Brain ageing is related to cognitive decline, which in turn diminishes essential cognitive functions like memory, critical thinking, and more. Brain ageing is also associated with neurodegenerative conditions like dementia and Alzheimer's. The scientific community is continuously trying to identify risk factors.
A study published in the journal Psychological Medicine has identified major depressive disorder's contribution to increasing brain age, showing how people with depression may have brains that appear older than their actual age.
Major depressive disorder, which is a clinical mental illness and not the same as a temporary low mood, alters the brain's structure. This accelerates brain ageing, making it appear much older than a person's actual age. The researchers behind the study aimed to examine this connection by analysing brain scans of 670 individuals, 239 with depression and the rest without. They estimated brain age by assessing the thickness of various brain regions.
And indeed, in people with depression, their brains appeared much older than those who were not diagnosed with the mental disorder. The changes were found in the brain's structure itself, especially in parts of the left ventral region and the premotor eye field, which showed significant thinning.
Since the brain is fundamental for cognitive functions like attention, memory, reasoning, and self-control, the study's findings show new insights into how these abilities may weaken in people with depression.
The study also explained the reasons behind the thinning in certain brain areas. The researchers found a connection between brain thinning and neurotransmitter levels such as dopamine, serotonin, and glutamate. These are important for managing mood and cognitive abilities. When someone is depressed, the levels of these neurotransmitters become imbalanced, which causes changes in the brain's structure. Moreover, certain genes may also be active in the affected regions, influencing protein binding. It is also important to note that depression has a genetic aspect, too, which means certain genes increase depression chances.
This is why it becomes crucial to value mental health conditions as much as physical health. Often, many are in the habit of downplaying it, trivialising it in comparison to physical ailments, but from this study findings it can be understood that depression has a physical impact as well, indicating that it is more than just a mood disorder.
Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NDTV
16 hours ago
- NDTV
Abortion Pill Inventor Etienne-Emile Baulieu Dies At 98
Rome: French scientist Etienne-Emile Baulieu, best known as the inventor of the abortion pill, died on Friday aged 98 at his home in Paris, his institute said in a statement. Both a doctor and a researcher, Baulieu was known around the world for the scientific, medical and social significance of his work on steroid hormones. "His research was guided by his attachment to the progress made possible by science, his commitment to women's freedom, and his desire to enable everyone to live better, longer lives," the Institut Baulieu said in the statement posted on its website. Born Etienne Blum in Strasbourg on Dec. 12, 1926, he took the name "Emile Baulieu" when he joined the French Resistance against the Nazi occupation at the age of 15. An endocrinologist with a doctorate in medicine completed in 1955 and one in science eight years later, in 1963 Baulieu founded a pioneering research unit working on hormones at INSERM, the French institute for health and medical research. He remained as head of the unit until 1997. He is best known for his development, in 1982, of RU 486, the so-called "abortion pill" that changed the lives of millions of women throughout the world, offering them the possibility of voluntary medical termination of pregnancy, in physical and psychological safety. The Institut Baulieu said it was "a non-invasive method, less aggressive and less delayed than surgery," noting that following his discovery the researcher faced fierce criticism and even threats from opponents of women's abortion rights. "Even today, access to this method is opposed, banned in some countries, and is currently being challenged in the United States, where it is the most widely used abortion method," the institute added. Baulieu's research into DHEA, a hormone whose secretion and anti-aging activity he had discovered, led him to work on neurosteroids -- or steroids of the nervous system. He also developed an original treatment to combat depression, for which a clinical trial is currently underway in several university hospitals. In 2008, he founded the Institut Baulieu to understand, prevent and treat neurodegenerative diseases such as Alzheimer's. Honored with the grand crosses of the Légion d'honneur (legion of honor) and the Ordre national du Mérite (national order of merit), he was elected to the French Academy of Sciences in 1982, which he chaired in 2003 and 2004. He was a member of the national advisory committee on life sciences and health (1996-2002) and received numerous awards, both in France and abroad. French President Emmanuel Macron paid tribute to Baulieu in a post on X, calling him "a beacon of courage" and "a progressive mind who enabled women to win their freedom." "Few French people have changed the world to such an extent," he added. After the death of his first wife, Yolande Compagnon, he remarried, to Simone Harari Baulieu. He is survived by three children, eight grandchildren and nine great-grandchildren, his institute said.
Mint
a day ago
- Mint
How much coffee is too much?
HUMANITY DRINKS around 2bn cups of coffee every day. The good news for those who contribute to that figure is that regularly consuming moderate amounts does not appear to be harmful. There may even be health benefits. Experiments conducted in vitro and in animals have long shown that key components of coffee, including cafestol, kahweol, caffeine and chlorogenic acids, can reduce inflammation as well as cell damage caused by a chemical process known as oxidation. When a team led by Marzieh Moeenfard of the University of Porto looked more closely, they found that the potential benefits ran deeper. She reported in the Journal of Cellular Biochemistry in 2016 that cafestol and kahweol (which tend to be more prevalent in unfiltered than in filtered coffee) arrested tumour growth by making it less likely that new blood vessels would form around tumour cells, and that chlorogenic acids inhibited the formation of carcinogens within the body. This suggested coffee might be good for fending off cancer. One follow-up study led by Jin-Kyoung Oh of the Karolinska Institute in Stockholm reported in the International Journal of Cancer that post-menopausal women who claimed to drink three or four cups of coffee per day were significantly less likely to develop breast cancer than women who said they drank up to two cups. Similar work in Japan suggested that those who said they drank three or more cups of coffee every day was associated with a reduced risk of developing liver cancer. Because caffeine is a stimulant that improves mood, enhances vigilance and combats tiredness, its presence in coffee has prompted some labs to test whether it reduces the risk of a person developing psychiatric and neurological diseases like Alzheimer's, Parkinson's and depression. Some have found beneficial effects. For example, Hong Chien-Tai of Taipei Medical University reported in Nutrients in 2020 that patients with Parkinson's who consumed caffeine regularly had their disease progress more slowly than those who abstained. Other findings, whether on cancer or mental health, have yielded mixed results. The uncertainty may well come down to the multitudes that coffee contains. Beans are sourced from different species, roasted in different fashions and served up in a variety of drinks of different sizes and strengths. Still, moderate consumption seems, at worst, harmless. Overindulgence has clearer-cut consequences. Ingesting more than 400 milligrams of caffeine daily (an espresso contains around 60) has been found to lead to headaches, nervousness, irritability, muscle tremors and insomnia. It is also associated with mental-health conditions such as anxiety, and can make chronic health problems, like heart disease, worse by increasing blood pressure. The effects of overdosing on coffee's other active ingredients are unclear. But these are not the only risks associated with drinking coffee. Many lace their cup with additives like milk, sugar, cream and syrup, chronic overconsumption of which can also have negative impacts on the body. Though the amount included in coffee is unlikely to be harmful on its own, sugar and syrup can predispose people to metabolic diseases like type 2 diabetes, for example, while whole milk and cream raise cholesterol levels and increase the risk of heart attack. To maximise the chance of feeling any potential benefits, don't overdo the cups and take it as black—and as bitter—as you like.© 2025, The Economist Newspaper Limited. All rights reserved. From The Economist, published under licence. The original content can be found on
Time of India
a day ago
- Time of India
AU experts develop compounds that may boost human memory
Prayagraj: In a breakthrough development, scientists from Allahabad University (AU) have identified 14 chemical compounds that could significantly enhance human memory. These compounds, developed in the university's chemistry laboratory, show promising effects in opening constricted brain neurons, which are often associated with memory loss and cognitive decline. Tired of too many ads? go ad free now The research, led by Prof Ramendra Kumar Singh of the Department of Chemistry at AU, marks a major advancement in the search for memory-enhancing drugs. Remarkably, the compounds developed in the Prayagraj-based university are currently undergoing international testing in laboratories in the United States, specifically at California State University, Fullerton. According to Prof Singh, preliminary results from the testing of three compounds showed positive outcomes, suggesting their potential in combating memory-related disorders. A research paper detailing this discovery was recently published in the Netherlands-based scientific journal, Journal of Molecular Structure, further highlighting the global relevance of this work. Explaining the scientific basis of the study, Prof Singh said that hyperphosphorylated tau proteins—proteins with an excess of phosphate groups—are responsible for memory degradation in humans. These proteins accumulate in the brain due to a deficiency of a neurotransmitter called acetylcholine. The enzyme acetylcholinesterase is responsible for breaking down acetylcholine, thus leading to its depletion. The 14 newly developed compounds aim to inhibit the function of acetylcholinesterase, thereby maintaining healthy acetylcholine levels and potentially improving memory and brain health. To identify these compounds, the research team conducted a series of chemical reactions in the lab and utilised computational techniques such as molecular docking and computer simulation to evaluate the compounds' activity and cytotoxicity. Tired of too many ads? go ad free now The detailed analysis confirmed that all 14 compounds showed significant promise in both effectiveness and safety. These compounds, after being encoded, were sent to California for second-phase testing on specific cell lines known to produce the tau protein responsible for Alzheimer's disease. Although the names of the compounds have not yet been disclosed, Prof Singh noted that the early-stage results are encouraging, with three compounds already delivering positive findings. The next steps in the research include developing a drug based on the most effective molecule. If successful, this could lead to a new therapeutic option for millions suffering from memory loss and neurodegenerative conditions like Alzheimer's.
